Pneumonia, Viral: Clinical Trials

8,029 trials for Pneumonia, Viral, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4419 completed, 2054 unknown, 563 terminated, 383 withdrawn. 1891 Not applicable, 1463 Phase 2, 939 Phase 3, 686 Phase 1, 251 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable1891Completed 1152, Unknown 417, Recruiting 78, Withdrawn 78, Terminated 75, Active not recruiting 48, Not yet recruiting 27, Enrolling by invitation 9, Suspended 7
Phase 21463Completed 670, Unknown 321, Terminated 246, Withdrawn 134, Recruiting 42, Active not recruiting 27, Not yet recruiting 13, Suspended 7, Enrolling by invitation 3
Phase 3939Completed 416, Unknown 238, Terminated 147, Withdrawn 85, Recruiting 22, Active not recruiting 13, Suspended 11, Not yet recruiting 6, Enrolling by invitation 1
Phase 1686Completed 383, Unknown 141, Terminated 68, Withdrawn 52, Recruiting 19, Active not recruiting 14, Not yet recruiting 9
Phase 4251Completed 116, Unknown 79, Terminated 24, Withdrawn 13, Recruiting 9, Active not recruiting 6, Suspended 3, Not yet recruiting 1
Early Phase 162Unknown 23, Completed 21, Terminated 6, Withdrawn 5, Suspended 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1

Follow Pneumonia, Viral: new trials by email Literature Review of Pneumonia, Viral trials Research Report on Pneumonia, Viral

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Perceptions of Undergraduate Students and Teaching Staff on Online Teaching
Questionnaire - Covid19
SuspendedMisr International University92092027-07-152026-10-08
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19
Phase 1 / Phase 2Not yet recruitingKimera Labs Inc.642027-01-012026-06-24
Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia
Health Communication, Health Communication + Structural - COVID-19, Vaccine Hesitancy
Not applicableWithdrawnMarc Kiviniemi2027-01-012026-11-06
Taurine Supplementation in Adolescents With Post-COVID Condition
Taurine - Long COVID, Post COVID-19 Condition
Phase 1 / Phase 2Not yet recruitingUniversity of Alberta302026-12-302026-10-16
CD19-B Cell Depletion in PAIS-ME/CFS Patients
Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID)
Phase 2Not yet recruitingCharite University, Berlin, Germany382026-12-012026-07-24
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
AVM0703, Placebo - ARDS, Covid19
Phase 1Not yet recruitingAVM Biotechnology Inc162026-12-012026-11-02
Dapagliflozin for Long COVID Syndrome
Dapagliflozin (DAPA), Placebo - COVID - 19, Long COVID Syndrome
Phase 3Not yet recruitingOttawa Heart Institute Research Corporation1922026-12-012026-10-30
Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections
Baseline MxA testing, Serial MxA testing, MxA result feedback and antiviral treatment recommendations - Respiratory Viral Infections, Influenza
Not applicableNot yet recruitingCapital Medical University6182026-11-302026-10-23
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Keytruda - Post-Acute COVID-19 Syndrome
Phase 1Not yet recruitingNational Institute of Neurological Disorders and Stroke (NINDS)152026-11-182026-11-13
The Study of Brave-LC LDN Treatment Trial
naltrexone, Placebo - Post-acute COVID-19 Syndrome
Phase 3Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)13002026-11-162026-11-04
Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome
Rimonabant, Placebo - Post-COVID-19 Syndrome
Phase 2Not yet recruitingSinfatin S.L802026-11-062026-11-12
Fatigue in Long COVID
Lightning Process, Activity Pacing - Long COVID
Not applicableNot yet recruitingMcMaster University1002026-11-012026-07-13
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
Flu A/B/COVID-19 + RSV Multiplex Rapid Test - SARS-CoV-2 Infection, Influenza A
Not applicableNot yet recruitingCorDx, Inc.15002026-11-012026-10-15
Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region
Vaccination Coverage Among Pregnant Women
Not yet recruitingAssistance Publique - Hôpitaux de Paris16052026-11-012026-10-20
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
RVX-sCPD9 - COVID -19
Phase 1Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)802026-10-262026-11-13
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Valacyclovir, Celecoxib, Paxlovid - Post-acute Sequelae of COVID-19, Long COVID
Phase 2RecruitingIcahn School of Medicine at Mount Sinai1502026-10-202026-10-28
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Active not recruitingIstituti Clinici Scientifici Maugeri SpA10002026-10-122026-11-04
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
mRNA-1273, mRNA-1283 - SARS-CoV-2
Phase 4RecruitingModernaTX, Inc.6002026-10-092026-11-04
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
Cryotherapy - ME/CFS, Fibromyalgia (FM)
Not applicableRecruitingOxford Brookes University402026-10-052026-11-05
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)
Aripiprazole (low-dose, 1mg), Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
Phase 2Not yet recruitingChristiana Franke1382026-10-012026-07-20

Showing 20 of 8029. Sign in to see all of them.

Narrower conditions

COVID-19 (7575)  ·  Coronavirus Infections (795)  ·  Post-Acute COVID-19 Syndrome (600)  ·  Severe Acute Respiratory Syndrome (272)  ·  Pneumonia (217)  ·  Respiratory Distress Syndrome (206)  ·  Anxiety Disorders (177)  ·  Virus Diseases (137)  ·  Depression (129)  ·  Influenza, Human (120)  ·  Respiratory Insufficiency (117)  ·  Motor Activity (105)  ·  Fatigue (93)  ·  Neoplasms (86)

Broader conditions

Respiratory Tract Diseases (8007)  ·  Lung Diseases (7990)  ·  Nidovirales Infections (7963)  ·  RNA Virus Infections (7957)  ·  Coronaviridae Infections (7956)  ·  Respiratory Tract Infections (7953)  ·  Infections (7944)  ·  Virus Diseases (7892)  ·  Pneumonia (7812)  ·  Coronavirus Infections (7187)  ·  Pathological Conditions, Signs and Symptoms (1597)  ·  Pathologic Processes (1282)  ·  Disease Attributes (909)  ·  Chronic Disease (668)

Interventions

Standard of Care (177)  ·  Hydroxychloroquine (165)  ·  Surveys and Questionnaires (114)  ·  BNT162 Vaccine (109)  ·  Blood Specimen Collection (108)  ·  Sodium Chloride (90)  ·  COVID-19 Vaccines (85)  ·  remdesivir (82)  ·  Saline Solution (77)  ·  2019-nCoV Vaccine mRNA-1273 (73)  ·  Ivermectin (68)  ·  Azithromycin (61)  ·  sinovac COVID-19 vaccine (56)  ·  nirmatrelvir and ritonavir drug combination (48)  ·  tocilizumab (48)

Sponsors

Assistance Publique - Hôpitaux de Paris (112)  ·  Assiut University (78)  ·  Pfizer (67)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (62)  ·  University Hospital, Strasbourg, France (57)  ·  Duke University (43)  ·  University Hospital, Montpellier (43)  ·  AstraZeneca (38)  ·  Cairo University (38)  ·  Ain Shams University (36)  ·  ModernaTX, Inc. (34)  ·  Hospices Civils de Lyon (32)  ·  Mayo Clinic (32)  ·  BioNTech SE (29)  ·  Central Hospital, Nancy, France (29)

Countries

United States (1935)  ·  France (762)  ·  China (434)  ·  Turkey (Türkiye) (426)  ·  Spain (422)  ·  Italy (390)  ·  United Kingdom (353)  ·  Brazil (318)  ·  Canada (301)  ·  Egypt (251)  ·  Germany (249)  ·  Mexico (195)  ·  Belgium (174)  ·  Russia (157)  ·  Argentina (118)

Top investigators

Mike Royal, MD (16)  ·  Adrian Hernandez, MD (9)  ·  Susanna Naggie, MD (8)  ·  Mikhail Samsonov (7)  ·  Neha Sharma (7)  ·  Sabine Hazan, MD (7)  ·  Tao Huang (7)

Results publications

PMID 34473343, PMID 35244208, PMID 35713300, PMID 31986264, PMID 32031570, PMID 32109013, PMID 32171076, PMID 32091533, PMID 33502773, PMID 34013969, PMID 36734509, PMID 37162745, PMID 36695483, PMID 37489818, PMID 37591523, PMID 34658014, PMID 32167524, PMID 34350582, PMID 32192578, PMID 32007143, PMID 32142651, PMID 32250385, PMID 38597249, PMID 32105632, PMID 33044747, PMID 33757717, PMID 36435633, PMID 32085846, PMID 32205204, PMID 33301246, PMID 33306989, PMID 35695334, PMID 39903535, PMID 15616839, PMID 21435708, PMID 27344959, PMID 31978945, PMID 31995857, PMID 32020029, PMID 32105637, PMID 32112977, PMID 32125452, PMID 32219428, PMID 32251768, PMID 32445440, PMID 32678530, PMID 32738928, PMID 32788708, PMID 33240091, PMID 33570583

NIH funding

2023 (22), U24TR001608 (8), 2025 (5), R25MH071584 (5), 1OT2HL156812-01 (4), P30CA033572 (4), OT2HL156812 (3), P30CA138292 (3), R01MD016328 (3), 1OT2HD107558-01 (2), 3UL1TR002538-03S2 (2), 3UM1AI068614-14S1 (2), 5UM1AI068614-14 (2), 5UM1AI148373-05 (2), 5UM1AI148684-02 (2)